LIFECORE BIOMEDICAL, INC. Deferred Revenue Recognized
LIFECORE BIOMEDICAL, INC. (LFCR) reported Deferred Revenue Recognized of $328.00 thousand for the 3-month period ending 2024-11-24, per its 10-Q filed 2025-01-02.
Financial Statements › Income Statement › Other Income
us-gaap:ContractWithCustomerLiabilityRevenueRecognized · last filed 2025-01-02
- LIFECORE BIOMEDICAL, INC. contract with customer, liability, revenue recognized for the quarter ending 2024-11-24 was $328.00K, a 80.71% decline year-over-year.
- LIFECORE BIOMEDICAL, INC. contract with customer, liability, revenue recognized for the quarter ending 2024-08-25 was $1.58M, a 21.71% decline year-over-year.
- LIFECORE BIOMEDICAL, INC. contract with customer, liability, revenue recognized for the quarter ending 2024-02-25 was $1.50M, a 1400.00% increase year-over-year.
- LIFECORE BIOMEDICAL, INC. contract with customer, liability, revenue recognized for the quarter ending 2023-11-26 was $1.70M, a 1600.00% increase year-over-year.
- LIFECORE BIOMEDICAL, INC. contract with customer, liability, revenue recognized for fiscal 2024 was $6.80M, a 1033.33% increase from fiscal 2023.
- LIFECORE BIOMEDICAL, INC. contract with customer, liability, revenue recognized for fiscal 2023 was $600.00K, a 50.00% increase from fiscal 2022.
- LIFECORE BIOMEDICAL, INC. contract with customer, liability, revenue recognized for fiscal 2022 was $400.00K.
- LIFECORE BIOMEDICAL, INC. contract with customer, liability, revenue recognized for fiscal 2020 was $200.00K, a 91.67% decline from fiscal 2019.
| Period end | Contract with Customer, Liability, Revenue Recognized 3 month | Contract with Customer, Liability, Revenue Recognized 3 month as first filed | Contract with Customer, Liability, Revenue Recognized 6 month | Contract with Customer, Liability, Revenue Recognized 9 month | Contract with Customer, Liability, Revenue Recognized 9 month as first filed | Contract with Customer, Liability, Revenue Recognized 12 month |
|---|---|---|---|---|---|---|
| 2024-11-24 | $328.00K 10-Q · filed 2025-01-02 | $1.91M 10-Q · filed 2025-01-02 | ||||
| 2024-08-25 | $1.58M 10-Q · filed 2024-10-04 | |||||
| 2024-05-26 | $6.80M 10-K · filed 2024-08-26 | |||||
| 2024-02-25 | $1.50M 10-Q · filed 2024-08-09 | $5.20M 10-Q · filed 2024-08-09 | ||||
| 2023-11-26 | $1.70M 10-Q · filed 2024-08-09 | $3.70M 10-Q · filed 2024-08-09 | ||||
| 2023-08-27 | $2.02M 10-Q · filed 2024-10-04 | $2.00M 10-Q · filed 2024-08-09 | ||||
| 2023-05-28 | $600.00K 10-K · filed 2024-08-26 | |||||
| 2023-02-26 | $100.00K 10-Q · filed 2024-08-09 | $500.00K 10-Q · filed 2023-06-02 | $500.00K 10-Q · filed 2024-08-09 | $100.00K 10-Q · filed 2023-06-02 | ||
| 2022-11-27 | $100.00K 10-Q · filed 2024-08-09 | $400.00K 10-Q · filed 2024-08-09 | ||||
| 2022-08-28 | $300.00K 10-Q · filed 2024-08-09 | |||||
| 2022-05-29 | $400.00K 10-K · filed 2024-08-26 | |||||
| 2022-02-27 | $0.00 10-Q · filed 2022-04-07 | $200.00K 10-Q · filed 2022-04-07 | ||||
| 2021-11-28 | $0.00 10-Q · filed 2022-01-07 | $200.00K 10-Q · filed 2022-01-07 | ||||
| 2021-08-29 | $200.00K 10-Q · filed 2021-10-05 | |||||
| 2021-02-28 | $0.00 10-Q · filed 2021-04-08 | $0.00 10-Q · filed 2021-04-08 | ||||
| 2020-11-29 | $0.00 10-Q · filed 2021-01-07 | |||||
| 2020-08-30 | $0.00 10-Q · filed 2020-10-07 | |||||
| 2020-05-31 | $200.00K 10-K · filed 2020-08-14 | |||||
| 2020-02-23 | $0.00 10-Q · filed 2020-04-03 | $200.00K 10-Q · filed 2020-04-03 | ||||
| 2019-11-24 | $100.00K 10-Q · filed 2020-01-02 | $200.00K 10-Q · filed 2020-01-02 | ||||
| 2019-08-25 | $100.00K 10-Q · filed 2019-10-03 | |||||
| 2019-05-26 | $2.40M 10-K · filed 2019-08-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B |